Introduction:
This quiz collection on SUPAC changes is designed specifically for M.Pharm students preparing for advanced coursework in documentation and regulatory writing. It summarizes key regulatory concepts related to post‑approval changes — including SUPAC-IR, SUPAC-MR and SUPAC-SS guidance — and tests understanding of change levels, required documentation, in vitro comparability criteria, and when bioequivalence or additional validation is needed. Questions emphasize practical scenarios students will encounter in regulatory submissions, focusing on critical process and formulation attributes (e.g., scale‑up, excipient changes, particle size, dissolution) and the documentation strategies used to demonstrate product quality and equivalence after changes. This set is concise, exam‑oriented and answer‑keyed for self‑assessment.
Q1. What is the primary purpose of SUPAC guidance documents?
- To provide manufacturing batch records for contract manufacturers
- To outline a framework for evaluating the impact of post‑approval manufacturing changes on product quality
- To replace all national regulatory requirements for medicinal products
- To establish clinical trial protocols for new drugs
Correct Answer: To outline a framework for evaluating the impact of post‑approval manufacturing changes on product quality
Q2. Which product types have specific SUPAC guidances?
- Only sterile injectables
- Immediate‑release (IR) oral solid dosage forms, modified‑release (MR) oral solid dosage forms, and non‑sterile semisolid dosage forms
- Only compounded pharmacy preparations
- Biologics and vaccines exclusively
Correct Answer: Immediate‑release (IR) oral solid dosage forms, modified‑release (MR) oral solid dosage forms, and non‑sterile semisolid dosage forms
Q3. In SUPAC terminology, what does a Level 1 change typically represent?
- A major change requiring new clinical studies
- A moderate change requiring additional validation and supporting data
- A minor change with minimal or no effect on product quality and typically requiring only reportable documentation
- A change that automatically triggers product recall
Correct Answer: A minor change with minimal or no effect on product quality and typically requiring only reportable documentation
Q4. Which of the following is commonly considered a Level 3 (major) SUPAC change for an immediate‑release tablet?
- Changing excipient supplier with same grade and specifications
- Increasing tablet potency by small incremental adjustments within specification
- Changing the manufacturing site of the primary compression/drying steps
- Switching to a different tablet press model with similar compression profile and documented equivalence
Correct Answer: Changing the manufacturing site of the primary compression/drying steps
Q5. For SUPAC‑IR, which in vitro criterion is frequently used to support that a post‑approval change has no effect on drug release?
- Similarity factor f2 with values between 50 and 100
- Relative standard deviation (RSD) > 50%
- Comparing only color and odor of the product
- Presence of any change in tablet hardness
Correct Answer: Similarity factor f2 with values between 50 and 100
Q6. When scaling up batch size, which SUPAC consideration is most critical to demonstrate equivalence?
- Only the change in batch number is recorded; no testing is needed
- Demonstrating comparable critical process parameters, in‑process controls, and product quality attributes, including dissolution
- Eliminating end‑product QC testing to save time
- Replacing all excipients with cheaper alternatives
Correct Answer: Demonstrating comparable critical process parameters, in‑process controls, and product quality attributes, including dissolution
Q7. Which scenario would most likely require a bioequivalence study rather than only in vitro testing under SUPAC?
- Minor change in tablet color additive
- Change in particle size distribution of a BCS Class II drug that may affect dissolution and absorption
- Changing label artwork without changing formulation
- Switching to a new secondary packaging carton
Correct Answer: Change in particle size distribution of a BCS Class II drug that may affect dissolution and absorption
Q8. SUPAC‑SS guidance applies primarily to which product form?
- Oral solutions and suspensions only
- Non‑sterile semisolid dosage forms such as creams, ointments and gels
- Sterile ophthalmic solutions
- Parenteral emulsions
Correct Answer: Non‑sterile semisolid dosage forms such as creams, ointments and gels
Q9. What is the recommended approach in SUPAC when changing an excipient to one with different functional properties?
- No documentation is needed if the new excipient is cheaper
- Perform risk assessment, provide comparative characterization (e.g., functionality, compatibility), and conduct necessary in vitro or in vivo studies
- Only update the invoice and shipping documents
- Reduce manufacturing controls to increase yield
Correct Answer: Perform risk assessment, provide comparative characterization (e.g., functionality, compatibility), and conduct necessary in vitro or in vivo studies
Q10. Which of the following changes is typically categorized as Level 2 (moderate) under SUPAC‑IR?
- Minor change in equipment vendor with identical design and validated equivalence
- Change in the composition of the immediate‑release tablet that alters the dissolution profile outside similarity limits
- Scale‑up within certain limits that may require additional testing and documentation but not new clinical studies
- Changing the marketing authorization holder
Correct Answer: Scale‑up within certain limits that may require additional testing and documentation but not new clinical studies
Q11. SUPAC guidance expects documentation of post‑approval changes to include which of the following?
- Only the batch production record with no justification
- Rationale for change, risk assessment, comparative data (e.g., dissolution), and any relevant validation or stability studies
- Only financial impact assessments
- Customer feedback surveys exclusively
Correct Answer: Rationale for change, risk assessment, comparative data (e.g., dissolution), and any relevant validation or stability studies
Q12. Which dissolution testing outcome would support that a post‑approval change has not altered in‑vivo performance for an IR product?
- f2 value of 35 between pre‑ and post‑change profiles
- f2 value of 65 between pre‑ and post‑change profiles
- Complete lack of dissolution in both samples
- Drastic change in tablet weight without dissolution data
Correct Answer: f2 value of 65 between pre‑ and post‑change profiles
Q13. In SUPAC, changing a lubricant type (e.g., magnesium stearate to stearic acid) would most likely require assessment because lubricants can affect:
- Only color of the tablet
- Powder flow, compression characteristics, surface hydrophobicity and dissolution
- Only the packaging compatibility
- Shipping temperature alone
Correct Answer: Powder flow, compression characteristics, surface hydrophobicity and dissolution
Q14. What role does process validation play in SUPAC change submissions?
- Process validation is irrelevant for post‑approval changes
- Validation demonstrates the process remains capable and consistent after a change; may be required for moderate or major changes
- Only end‑customer testing replaces validation
- Validation documents are strictly proprietary and never submitted
Correct Answer: Validation demonstrates the process remains capable and consistent after a change; may be required for moderate or major changes
Q15. Which parameter would be most important to monitor when changing the mill used for particle size reduction?
- Tablet embossing pattern
- Particle size distribution and related dissolution behavior
- Font size on the label
- Color of the milling equipment
Correct Answer: Particle size distribution and related dissolution behavior
Q16. If a post‑approval change results in altered impurities profile, SUPAC recommends:
- Ignoring impurities as long as potency is unchanged
- Conducting impurity identification, assessing toxicological relevance, and performing additional stability or safety studies as needed
- Reducing potency to compensate for impurity levels
- Only notifying the marketing team
Correct Answer: Conducting impurity identification, assessing toxicological relevance, and performing additional stability or safety studies as needed
Q17. SUPAC guidance often references equivalence of critical quality attributes. Which of the following is NOT typically considered a critical quality attribute for solid oral dosage forms?
- Dissolution profile
- Assay (potency)
- Tablet friability and hardness
- Invoice price of excipients
Correct Answer: Invoice price of excipients
Q18. During a manufacturing site change, what documentation is essential to include in the SUPAC submission?
- Only photos of the new facility lobby
- Comparative validation data, process description, equipment equivalence, stability data and quality control results
- Employee HR records
- Marketing budget for the new site
Correct Answer: Comparative validation data, process description, equipment equivalence, stability data and quality control results
Q19. For SUPAC‑MR (modified release), which additional aspect is particularly critical compared to SUPAC‑IR?
- Only the color of coating matters
- The release mechanism (e.g., diffusion, erosion) and maintaining the targeted release kinetics across the dosing interval
- Eliminating any dissolution testing since release is prolonged
- Using a single dissolution time point is always sufficient
Correct Answer: The release mechanism (e.g., diffusion, erosion) and maintaining the targeted release kinetics across the dosing interval
Q20. Which statistical or analytical approach is commonly used to compare pre‑ and post‑change dissolution profiles under SUPAC?
- Only visual comparison without metrics
- Similarity factor (f2), and where applicable, model‑dependent or multivariate methods to compare profiles
- Comparing marketing claims on the label
- pH meter calibration records only
Correct Answer: Similarity factor (f2), and where applicable, model‑dependent or multivariate methods to compare profiles
